These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1556 related items for PubMed ID: 17145742

  • 1. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group.
    N Engl J Med; 2006 Dec 07; 355(23):2427-43. PubMed ID: 17145742
    [Abstract] [Full Text] [Related]

  • 2. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
    Dailey GE, Noor MA, Park JS, Bruce S, Fiedorek FT.
    Am J Med; 2004 Feb 15; 116(4):223-9. PubMed ID: 14969649
    [Abstract] [Full Text] [Related]

  • 3. [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
    Scheen AJ.
    Rev Med Liege; 2007 Jan 15; 62(1):48-52. PubMed ID: 17343130
    [Abstract] [Full Text] [Related]

  • 4. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B, Diabetes Outcome Progression Trial (ADOPT) Study Group.
    Diabetes Care; 2010 Jan 15; 33(1):177-83. PubMed ID: 19808911
    [Abstract] [Full Text] [Related]

  • 5. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI.
    Diabetes Care; 2002 Oct 15; 25(10):1737-43. PubMed ID: 12351470
    [Abstract] [Full Text] [Related]

  • 6. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
    Lewin A, Lipetz R, Wu J, Schwartz S.
    Clin Ther; 2007 May 15; 29(5):844-855. PubMed ID: 17697903
    [Abstract] [Full Text] [Related]

  • 7. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
    Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR, ADOPT Study Group.
    Diabetes; 2011 May 15; 60(5):1552-60. PubMed ID: 21415383
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE, ADOPT Study Group.
    J Clin Endocrinol Metab; 2010 Jan 15; 95(1):134-42. PubMed ID: 19875477
    [Abstract] [Full Text] [Related]

  • 11. A clinical trial to maintain glycemic control in youth with type 2 diabetes.
    TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F.
    N Engl J Med; 2012 Jun 14; 366(24):2247-56. PubMed ID: 22540912
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ, Bruce S, Fiedorek FT.
    Clin Ther; 2002 Sep 14; 24(9):1401-13. PubMed ID: 12380632
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.
    Clin Ther; 2007 Sep 14; 29(9):1900-14. PubMed ID: 18035190
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE, Mohideen P, Fiedorek FT.
    Clin Ther; 2002 Sep 14; 24(9):1426-38. PubMed ID: 12380634
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.